Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Fecal Microbiota Transplantation as add-on Therapy in Mild-to-moderate Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-60;~* Endoscopically and morphologically confirmed UC;~* Negative results of stool culture for the presence of pathogenic bacteria (Shigella spp., Salmonella spp., Campylobacter spp., Yersinia spp.) and toxin-producing Clostridioides difficile;~* partial Mayo score of 4-6;~* Mayo endoscopic subscore ≥1;~* Fecal calprotectin \> 150 mcg/g~* Treatment with mesalazine at a daily dose of 3 g during the last 4 weeks~Exclusion Criteria:~* Pregnancy, planning pregnancy or breastfeeding;~* Postponed operations on the abdominal cavity;~* Severe mental disorders, alcohol or drug abuse;~* Use of systemic corticosteroids, biological agents, and probiotics within 8 weeks before study~* Any condition or circumstance that would, in the opinion of the investigator, prevent completion of the study or interfere with analysis of study results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- standard care group (Type: ACTIVE_COMPARATOR): mesalazine (Pentasa) at a daily dose of 3 g (2 g orally + 1 g rectally)
- Fecal transplantation (Type: EXPERIMENTAL): Fecal transplantation of fresh prepared feces from healthy donor. Application by colonoscope in proximal half of colon.

Based on this trial design, predict the completion outcome and termination type (if applicable).